APA (7th ed.) Citation

Fernando, D., Dimelow, R., Gorey, C., Zhu, X., Muya, C., Parker, C., . . . Uings, I. (2022). Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo‐controlled first‐in‐human study in healthy volunteers. British journal of clinical pharmacology, 88(2), 865-870. https://doi.org/10.1111/bcp.15010

Chicago Style (17th ed.) Citation

Fernando, Disala, et al. "Assessment of the Safety, Pharmacokinetics and Pharmacodynamics of GSK3335065, an Inhibitor of Kynurenine Monooxygenase, in a Randomised Placebo‐controlled First‐in‐human Study in Healthy Volunteers." British Journal of Clinical Pharmacology 88, no. 2 (2022): 865-870. https://doi.org/10.1111/bcp.15010.

MLA (9th ed.) Citation

Fernando, Disala, et al. "Assessment of the Safety, Pharmacokinetics and Pharmacodynamics of GSK3335065, an Inhibitor of Kynurenine Monooxygenase, in a Randomised Placebo‐controlled First‐in‐human Study in Healthy Volunteers." British Journal of Clinical Pharmacology, vol. 88, no. 2, 2022, pp. 865-870, https://doi.org/10.1111/bcp.15010.